CANF Can-Fite BioPharma Ltd.
Price Chart
Executive Summary
Can-Fite BioPharma is facilitating the immediate cash exercise of existing warrants to purchase 795,869 ADSs at a reduced price of $5.00 per ADS (down from $9.34), generating approximately $4.0 million in gross proceeds. In exchange, the company will issue new unregistered warrants to purchase 1,591,738 ADSs at $5.00 per share, exercisable for 24 months, and has committed to file a resale registration statement. The proceeds will fund R&D, clinical trials, and general corporate purposes.
Key Financial Metrics
Actionable Insight
Traders should monitor the filing of the resale registration statement and assess potential near-term dilution from the new warrants, which could weigh on the stock. The $4M inflow provides modest runway for clinical development but does not materially alter the company's trajectory.
Key Facts
- Existing warrants for 795,869 ADSs are being exercised at $5.00 per ADS (reduced from $9.34).
- Gross proceeds from the exercise are expected to be $4.0 million.
- New unregistered warrants for 1,591,738 ADSs are being issued at $5.00 per ADS, exercisable for 24 months.
- Resale registration statement will be filed for the new warrants' underlying shares.
- Proceeds will be used for R&D, clinical trials, and working capital.
- H.C. Wainwright & Co. is the exclusive placement agent.
Financial Impact
$4.0 million in gross proceeds, with potential future dilution from 1.59 million new warrants.
Risk Factors
- Future dilution from the new warrants (nearly 2x the number of shares exercised).
- Proceeds are relatively small compared to market cap, limiting transformative impact.
- Unregistered nature of new warrants may limit investor appetite and create overhang risk.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249502 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
6-K
| $3.20 awaiting T+1 | awaiting T+1 | — | $2.84 (−11.25%) |
|
Jun 2, 2026
12d ago
|
6-K
| $3.11 $3.11 | · 0.00% | ▲ +0.69% | $2.84 (−8.68%) |
|
May 28, 2026
17d ago
|
6-K
| $3.35 $3.24 | ▼ −3.28% | ▼ −3.54% | $2.84 (−15.22%) |
|
May 13, 2026
4w ago
|
6-K
| $3.64 $3.49 | ▼ −4.12% | ▼ −4.90% | $2.84 (−21.98%) |
|
Apr 30, 2026
6w ago
|
6-K
| $3.19 $2.93 | ▼ −8.15% | ▼ −8.37% | $2.84 (−10.97%) |
|
Apr 23, 2026
7w ago
|
6-K
| $2.91 $2.92 | ▲ +0.34% | ▲ +0.18% | $2.84 (−2.41%) |
|
Apr 6, 2026
10w ago
|
EFFECT
| $3.06 $3.03 | ▼ −0.98% | ▼ −1.04% | $2.84 (−7.19%) |
|
Apr 1, 2026
10w ago
|
EFFECT
| $3.09 $3.07 | ▼ −0.65% | ▼ −0.73% | $2.84 (−8.09%) |
|
Mar 30, 2026
10w ago
|
6-K
| $3.01 $3.10 | ▲ +2.99% | ▲ +0.10% | $2.84 (−5.65%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $3.01 $3.10 | ▲ +2.99% | ▲ +0.10% | $2.84 (−5.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access